Adenovirus with Hexon Tat-Protein Transduction Domain Modification Exhibits Increased Therapeutic Effect in Experimental Neuroblastoma and Neuroendocrine Tumors

Oncolytic adenovirus modified with somatostatin motifs for selective infection of neuroendocrine tumor cells

(2011) J Leja et al.   GENE THERAPY

Oncolytic Viruses for the Treatment of Neuroendocrine Tumors

(2011) M. Essand et al.   HORMONE AND METABOLIC RESEARCH

Secondary structure of cell-penetrating peptides controls membrane interaction and insertion

(2010) Emelía Eiríksdóttir et al.   BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES

Varying Opinions on the Authenticity of a Human Midgut Carcinoid Cell Line - Letter

(2010) L. M. Ellis et al.   CLINICAL CANCER RESEARCH

Prolonged systemic circulation of chimeric oncolytic adenovirus Ad5/3-Cox2L-D24 in patients with metastatic and refractory solid tumors

(2010) S Pesonen et al.   GENE THERAPY

An ex vivo loop system models the toxicity and efficacy of PEGylated and unmodified adenovirus serotype 5 in whole human blood

(2010) A Danielsson et al.   GENE THERAPY

Potentiating Cancer Immunotherapy Using an Oncolytic Virus

(2010) Byram W Bridle et al.   MOLECULAR THERAPY

Targeting Localized Immune Suppression Within the Tumor Through Repeat Cycles of Immune Cell-oncolytic Virus Combination Therapy

(2010) Stephen H Thorne et al.   MOLECULAR THERAPY

Enhancing the Therapeutic Effect Against Ovarian Cancer Through a Combination of Viral Oncolysis and Antigen-specific Immunotherapy

(2010) Yu-Qian Zhang et al.   MOLECULAR THERAPY

Desmoglein 2 is a receptor for adenovirus serotypes 3, 7, 11 and 14

(2010) Hongjie Wang et al.   NATURE MEDICINE

Double-Detargeted Oncolytic Adenovirus Shows Replication Arrest in Liver Cells and Retains Neuroendocrine Cell Killing Ability

(2010) Justyna Leja et al.   PLoS One

Identification of coagulation factor (F)X binding sites on the adenovirus serotype 5 hexon: effect of mutagenesis on FX interactions and gene transfer

(2009) R. Alba et al.   BLOOD

Overcoming pre-existing adenovirus immunity by genetic engineering of adenovirus-based vectors

(2009) Sergey S Seregin et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Intracellulartransduction using cell-penetrating peptides

(2009) Rupa Sawant et al.   Molecular BioSystems

Expanded Anticancer Therapeutic Window of Hexon-modified Oncolytic Adenovirus

(2009) Elena V Shashkova et al.   MOLECULAR THERAPY

Transduction of adenovirus vectors modified with cell-penetrating peptides

(2009) Yusuke Eto et al.   PEPTIDES

Fiber Mediated Receptor Masking in Non-Infected Bystander Cells Restricts Adenovirus Cell Killing Effect but Promotes Adenovirus Host Co-Existence

(2009) Johan Rebetz et al.   PLoS One

Re-engineering adenovirus vector systems to enable high-throughput analyses of gene function

(2008) Richard J. Stanton et al.   BIOTECHNIQUES

Increased therapeutic efficacy of the prostate-specific oncolytic adenovirus Ad[I/PPT-E1A] by reduction of the insulator size and introduction of the full-length E3 region

(2008) A Danielsson et al.   CANCER GENE THERAPY

Adenovirus Serotype 5 Hexon Mediates Liver Gene Transfer

(2008) Simon N. Waddington et al.   CELL

Tat conjugation of adenovirus vector broadens tropism and enhances transduction efficiency

(2008) Yasuo Yoshioka et al.   LIFE SCIENCES

Targeting of Adenovirus Vectors to the LRP Receptor Family With the High-affinity Ligand RAP via Combined Genetic and Chemical Modification of the pIX Capsomere

(2008) Stéphanie Corjon et al.   MOLECULAR THERAPY

Substitution of Hexon Hypervariable Region 5 of Adenovirus Serotype 5 Abrogates Blood Factor Binding and Limits Gene Transfer to Liver

(2008) Frédéric Vigant et al.   MOLECULAR THERAPY

Protein Crystals in Adenovirus Type 5-Infected Cells: Requirements for Intranuclear Crystallogenesis, Structural and Functional Analysis

(2008) Laure Franqueville et al.   PLoS One